1. Simplified care-pathway selection for nonspecialist practice
- Author
-
Aliya Gulamhusein, Nora Cazzagon, Xavier Verhelst, Andrew Mason, Cyriel Y. Ponsioen, George N. Dalekos, Keith D. Lindor, Frederik Nevens, Palak J. Trivedi, Adriaan J. van der Meer, Kris V. Kowdley, Willem J Lammers, Olivier Chazouillères, Ana Lleo, Douglas Thorburn, Nikolaos K. Gatselis, Bettina E. Hansen, Carla F. Murillo Perez, Tony Bruns, Gideon M. Hirschfield, Pietro Invernizzi, Annarosa Floreani, Christophe Corpechot, Marco Carbone, Marlyn J. Mayo, Albert Parés, Pier Maria Battezzati, Harry L.A. Janssen, Gastroenterology & Hepatology, Murillo Perez, C, Gulamhusein, A, Carbone, M, Trivedi, P, van der Meer, A, Corpechot, C, Battezzati, P, Lammers, W, Cazzagon, N, Floreani, A, Pares, A, Nevens, F, Lleo, A, Mayo, M, Kowdley, K, Ponsioen, C, Dalekos, G, Gatselis, N, Thorburn, D, Mason, A, Janssen, H, Verhelst, X, Bruns, T, Lindor, K, Chazouilleres, O, Invernizzi, P, Hansen, B, Hirschfield, G, Gastroenterology and Hepatology, and Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Cholagogues and Choleretics ,medicine.medical_specialty ,Bilirubin ,Risk management tools ,Risk Assessment ,chemistry.chemical_compound ,Risk groups ,Internal medicine ,medicine ,Care pathway ,Humans ,In patient ,Hepatology ,Liver Cirrhosis, Biliary ,business.industry ,Ursodeoxycholic Acid ,Gastroenterology ,Fibrosis stage ,Middle Aged ,Alkaline Phosphatase ,pbc ,Young age ,chemistry ,Critical Pathways ,Alkaline phosphatase ,business - Abstract
BACKGROUND: Opportunity to redefine the care journeys for those living with primary biliary cholangitis (PBC) includes facilitating access to enhanced (PBC-dedicated) programmes by nonspecialist risk 'flagging' of patients. OBJECTIVE: To develop a nonexpert PBC stratification tool to help care pathway choices (standard vs. enhanced) choices in PBC. METHODS: We included ursodeoxycholic acid-treated patients with PBC from the Global PBC Study Group. The performance of baseline and 1-year clinical markers with transplant-free survival was assessed to develop the 'ABA' tool using Age (A), Bilirubin (B), and Alkaline phosphatase (A). Added value of fibrosis estimation was assessed. RESULTS: 'ABA' classification mapped three risk groups (n = 2226): low [Age > 50 years, bilirubin ≤ 1 × ULN, alkaline phosphatase (ALP) ≤ 3 × ULN], high (Age ≤ 50 years, bilirubin > 1 × ULN, ALP > 3 × ULN), and intermediate (other). Transplant-free survival at 10 years in the low-, intermediate-, and high-risk groups were 89, 77, and 59% at baseline and 86, 76, and 40% at 1 year, respectively. We propose that high-risk patients at baseline be directly triaged to enhanced (PBC-dedicated) care and the remaining be reassessed at 1 year. Modelling showed after 1 year 46% patients were proposed to enhanced care and 54% to standard care. The 'ABA' mapped pathways facilitated identification of patients at risk based on a young age, as compared to traditional liver biochemical stratification. In patients proposed to standard care, estimated fibrosis stage had ongoing prognostic value. CONCLUSION: Nonspecialist use of the 'ABA' risk tool could prioritize care journey choices for patients with PBC.
- Published
- 2021